Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics

Author(s): Francesca Carlomagno and Massimo Santoro

Volume 12, Issue 15, 2005

Page: [1773 - 1781] Pages: 9

DOI: 10.2174/0929867054367266

Price: $65

Abstract

Oncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particular, we examine the KIT, MET and RET receptors that are targeted by genetic alterations in both sporadic and familial human tumours.

Keywords: kinase, tyrosine, oncogene, germline, thyroid, kit, met, ret


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy